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Abstract: Circadian rhythm disturbances can occur as part of the clinical symptoms of major 
depressive disorder and have been found to resolve with antidepressant therapy. The pineal 
gland is relevant to circadian rhythms as it secretes the hormone melatonin following activation 
of the cyclic adenosine monophosphate (cAMP) signaling cascade and of arylalkylamine 
N-acetyltransferase (AA-NAT), the rate-limiting enzyme for its synthesis. Cyclic AMP is 
synthesized by adenylate cyclases (AC) and degraded by phosphodiesterases (PDEs). Little is 
known about the contribution of the PDE system to antidepressant-induced alterations in pineal 
cAMP signaling and melatonin synthesis. In the present study we used enzyme immunoassay to 
measure plasma melatonin levels and pineal cAMP levels and as well as quantitative real-time 
polymerase chain reaction to measure pineal expression of PDE, AC, and AA-NAT genes 
in rats chronically treated with the prototypic antidepressant fluoxetine. We found elevated 
melatonin synthesis with increased pineal AA-NAT gene expression and daytime plasma mela-
tonin levels and downregulated cAMP signaling with increased PDE and unchanged AC pineal 
gene expression, and decreased content of pineal cAMP. We conclude that chronic fluoxetine 
treatment increases daytime plasma melatonin and pineal AA-NAT gene expression despite 
downregulated pineal cAMP signaling in the rodent.
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Introduction
Multiple central nervous system (CNS) functions are dysregulated in major depressive 
disorder (MDD). Alterations in sleep, food intake, cognition, temperature, and 
neuroendocrine regulation are manifested as clinical symptoms in this chronic, highly 
disabling disorder.1 Clinical symptoms point to several brain areas of relevance to MDD 
pathophysiology including the pineal gland, HPA axis (hypothalamus, pituitary, adrenal 
glands), prefrontal cortex, and hippocampus. Circadian biorhythms have been found to 
occur with each of the above CNS functions.2 Furthermore, MDD and other mood dis-
orders are associated with disruptions in these rhythms that are normalized with chronic 
antidepressant treatment.3,4 MDD symptoms can vary through the 24-hour period, with 
more severe symptoms often occurring in the morning, consistent with a phase advance 
of circadian rhythms.5 Unfortunately, the mechanism by which repeated antidepressants 
operate to restore these circadian rhythm disturbances in MDD remains unclear.
The central clock or pacemaker in the brain, the suprachiasmatic nucleus (SCN), is 
located in the anterior hypothalamus and is responsible for the entrainment of behavioral 
and biochemical circadian rhythms. The SCN receives information from the environment 
in the form of ‘zeitgebers’ or synchronizing signals such as light. Light enters the retina 
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and is encoded by retinal ganglion cells into a message that 
is sent to the SCN via the retinohypothalamic tract. The SCN 
then sends projections via the paraventricular nucleus of the 
hypothalamus to affect the autonomic nervous system, the 
release of hormones from the pituitary, and the release of 
melatonin from the pineal gland. Brainstem raphe nuclei send 
serotonin/5-HT projections to the SCN, therefore the 5-HT 
system has been implicated in circadian rhythm disturbances.6 
The circadian secretion of melatonin by the pineal gland is 
under the influence of the SCN, with higher levels during at 
night (darkness) and lower levels during daytime (light), cor-
responding with the sleep-wake cycle. Levels of melatonin 
can cause a feedback regulation on the activity of the SCN 
by binding to melatonin type-1 and type-2 receptors (MT1 
and MT2) that are present in high concentrations in the SCN. 
Melatonin binding to MT1 receptors causes inhibition and 
binding to MT2 receptors results in a phase-shifting effect on 
SCN activity.7 The melatonergic agonist and 5HT2C antago-
nist agomelatine is a chronobiotic that not only resynchro-
nizes dysregulated circadian sleep patterns in MDD, but also 
demonstrates potential as a novel antidepressant, displaying 
superior efficacy versus placebo and similar efficacy versus 
other antidepressant drugs on depressive symptoms in several 
randomized controlled clinical trials thus far.8
The pineal gland can be used as a model system to 
study the effects of antidepressants on circadian rhythms, 
as signaling transduction cascades in the pineal have been 
extensively studied and the activation of these cascades is 
known to result in a well-defined output, the synthesis and 
secretion of melatonin.9 Dense sympathetic innervation 
from the superior cervical ganglion results in release of 
norepinephrine (NE) that binds to β1-adrenergic receptors 
(β1-AR) on pinealocytes. Stimulation of β1-AR leads to 
activation of the adenylate cycase (AC)/cyclic adenosine 
monophosphate (cAMP)/protein kinase A (PKA) signaling 
cascade, increased activity of the rate-limiting enzyme of 
melatonin synthesis arylalkylamine N-acetyltransferase 
(AA-NAT), and subsequently increased melatonin synthesis 
and secretion into the blood.
Treatment  with  pharmacologic  agents,  such  as 
antidepressants, that chronically increase synaptic NE and/or 
5-HT would be expected to affect the levels of signaling 
cascade intermediates. The amount of extracellular NE 
and 5-HT at the synapse and the duration of β1-AR and 
5HT2R stimulation could therefore influence pinealocyte 
metabolism and melatonin synthesis and secretion. However, 
the consequences of chronically increased extracellular NE or 
5-HT on pinealocyte metabolism remain unknown.9 Attenuated 
activation of intracellular signaling pathway might occur as a 
compensatory mechanism to stabilize pinealocyte metabolism 
and circadian rhythms. The compensatory decrease of the 
signaling cascade has been hypothesized to occur as a result of 
either receptor downregulation or decreased synthesis of second 
messenger intermediates. However, increased degradation of 
cyclic nucleotides could also regulate pinealocyte metabolism 
in response to antidepressants. Therefore, phosphodiesterases 
(PDEs) could play a role in mediating effects of chronic 
antidepressant treatment to restore dysregulated circadian 
rhythms by modulating levels of cyclic nucleotide intermediates 
in signaling transduction cascades.
The regulation of cyclic nucleotide levels occurs through 
the balance of production by cyclase enzymes and degradation 
by PDE enzymes. As second messengers in intracellular 
signaling transduction cascades, cyclic nucleotides can have 
important downstream consequences on gene expression and 
resultant neuronal responses. By modulating levels of cyclic 
nucleotides such as cAMP, the activity of PDE enzymes 
could potentially influence melatonin secretion, one such 
neuronal response in the pineal gland. In the present study, we 
have used enzyme immunoassay and quantitative real-time 
PCR to investigate changes in plasma melatonin, AA-NAT 
expression, PDE and AC expression, and cAMP levels in the 
pineal gland to determine the effects of chronic antidepressant 
treatment on the cAMP signaling and melatonin synthetic 
transduction cascades in the pineal gland.
Materials and methods
Animals and drug treatment
Virus- and antibody-free adult, male Sprague Dawley rats 
(150–200 g; Harlan, Indianapolis, IN) were housed two 
per cage at 24 °C with lights on from 06:00 to 18:00 hours 
in a stress-free environment for at least five days before 
the initiation of experimental procedures. Ten rats were 
randomly assigned to each experimental group: 1) control 
(0.9% saline) or 2) fluoxetine (selective serotonin reuptake 
inhibitor). All animals received daily (at 10:00 am) 0.5 mL 
intraperitoneal (i.p.) injections of either 0.9% saline (Hospira 
Inc., Lake Forest, IL) or 5.0 mg/kg fluoxetine (Eli Lilly, 
Indianapolis, IN) dissolved in 0.9% saline for eight weeks. 
The 5.0 mg/kg dose for fluoxetine is based on previous 
reports.10 We have previously utilized the chronic time course 
of eight weeks daily i.p. antidepressant injections and do not 
report any indication of inflammation or stress as a result 
of the injections. Furthermore, eight weeks daily treatment 
with 5 mg/kg fluoxetine i.p. has been reported to decrease 
expression of the corticotropin-releasing hormone gene in the 
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perviventricular nucleus of the hypothalamus, an effect that 
was not seen at two weeks.10 Therefore, eight weeks treatment 
was chosen as clinically antidepressants are effective after 
3–6 weeks.10 Animals were euthanized by decapitation and 
the pineal gland was dissected out, flash frozen, and stored 
at -80 °C. Animals received their last treatment 24 hours 
before termination of experiments and were sacrificed 
during the daytime, between 10:00 am and 12:00 pm. We 
selected this light cycle timepoint, corresponding to four to 
six hours after the dark/light transition, to study the effect 
of antidepressant treatment at the nadir of circadian cycles 
for melatonin synthesis and cAMP signaling to increase the 
likelihood of detecting significant differences. This experi-
mental protocol was approved by the University of Miami 
Institutional Animal Care and Use Committee.
Enzyme immunoassays (EIA)
Melatonin concentration in the plasma was determined using 
a competitive enzyme immunoassay kit (IBL Hamburg, 
Hamburg, Germany). Samples, standards, and controls 
were extracted, eluted, evaporated, and reconstituted; 
the test procedure was then performed as outlined in the 
manufacturer’s protocol. The concentration of melatonin is 
expressed as pg/mL.
Cyclic AMP levels in the pineal gland were determined 
using a direct, competitive enzyme immunoassay kit (Assay 
Designs, Ann Arbor, MI). Pineal glands were homogenized 
in 10 volumes of 0.1 M HCl and centrifuged 600 × g 
at room temperature. The supernatant was acetylated to 
improve signal detection and samples were run in duplicate. 
The concentration of cAMP is expressed as pmol/mL.
Quantitative real-time RT-PcR
Total RNA was isolated from pineal gland using RNeasy 
Lipid Mini Kit, quantified using a Nanodrop ND-1000 
spectrophotometer (Thermo-Fisher Scientific, Waltham, 
MA) and reverse transcribed to cDNA using Omniscript RT 
Kit (Qiagen, Hilden, Germany), random hexamer primers, 
and 250 ng RNA. Based on the results of a pilot study in 
which we surveyed all of the PDEs expressed in the pineal 
gland, we selected to follow up the results for PDE -4B, and 
-8B genes. PDE primers were designed in different exons 
to amplify cDNA using Primer Express software (Applied 
Biosystems, Foster City, CA). PDE4B (NM_017031) primers 
were: forward (5′-GTGACGAGCTCCGGTGTTC-3′) and 
reverse (5′-GCCGATACAACTCCAAGGACTT-3′).11 
PDE8B  (NM_199268)  primers  were:  forward 
(5′-GAAGCCGTGTGCAGGTCAAT-3′) and reverse 
(5′-AACCACAGCCAGGATCACTGT-3′).  AC1 
(NM_001107239) primers were: forward (5′-CCCCGGAA-
CATGGATCTCTATTA-3′) and reverse (5′-TGTTGTTGC-
CATCCAGTTCTATG-3′). AA-NAT (U40803) primers 
were: forward (5′-GAAGGGAGACAGCAGTTC-3′) and 
reverse (5′-GTCCTGGTCTTGCCTTTG-3′).12 Beta-Actin 
(NM_031144) primers were: forward (5′- GACCCA-
GATCATGTTTGAGACCTT-3′) and reverse (5′-AGAG-
GCATACAGGACAACACA-3′). A standard curve of 
pooled, serially diluted cDNA was run for each target gene 
and for a housekeeping gene, rat β-Actin, using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems). cDNA 
samples were diluted 1:250 and run in triplicate for both 
rat β-Actin and the gene of interest. The three SYBR cycle 
threshold (Ct) values were averaged for each sample, and 
the RNA input for the target gene was calculated from the 
standard curve. Fold changes in pineal gland target gene 
expression was expressed as a ratio to β-Actin expression 
for each sample.
Statistical analysis
The data were analyzed using Student’s t-test with the 
significance level set at p  0.05.
Results
Enzyme immunoassays
The levels of plasma melatonin were increased by chronic 
fluoxetine (+39%; p  0.05; t = 2.818, df = 17) (Figure 1b). 
Pineal gland cAMP levels were decreased by chronic fluox-
etine (-50%; p  0.01; t = 3.229, df = 13) (Figure 2b).
Quantitative real-time RT-PcR
Chronic treatment with fluoxetine increased the gene for 
the rate-limiting enzyme of melatonin synthesis, AA-NAT 
(+393%; p  0.001; t = 4.440, df = 17) (Figure 1a).
Chronic fluoxetine increased the expression of two 
cAMP-specific PDEs, PDE4B (+140%; p  0.001; 
t = 4.077, df = 17) and PDE8B (+68%; p  0.01; t = 3.219, 
df = 18). Expression of the predominant adenylate cyclase 
isoform, AC1, was unchanged (p  0.05; t = 0.1768, 
df = 16) (Figure 2a).
Discussion
In the present study, we provide evidence of increased daytime 
melatonin synthesis in the rodent following eight weeks sustained 
treatment with the prototypic antidepressant fluoxetine. In order 
to understand the effect of chronic treatment with fluoxetine on 
the melatonin synthetic cascade, we measured expression of the 
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AA-NAT gene in the pineal gland and found five-fold increased 
expression of AA-NAT following chronic fluoxetine. We then 
measured blood plasma melatonin using enzyme immunoas-
say to determine the consequences of increased AA-NAT 
gene expression in the pineal gland. We predicted that plasma 
melatonin levels would be elevated following chronic fluoxetine 
because of the findings of increased transcription of the gene 
for the rate-limiting enzyme of melatonin synthesis, AA-NAT. 
Plasma melatonin levels were increased following chronic fluox-
etine. We took blood samples during the light cycle, when plasma 
melatonin levels are usually at their nadir, and were able to detect 
an increase. Our finding of increased plasma melatonin is in 
contrast with one study that found melatonin unaltered following 
chronic imipramine (IMI)13 and other studies that have found 
chronic treatment (10 days to three weeks) with monoamine 
oxidase inhibitors,13,14 IMI,15,16 desipramine,17 and venlafaxine18 
decreased or attenuated increases in plasma or pineal melatonin, 
its precursors, and/or melatonin synthetic enzyme activity. We 
administered fluoxetine, a selective serotonin reuptake inhibitor, 
chronically for eight weeks, whereas other studies administered 
tricyclic antidepressants for 10 days to three weeks; therefore, 
differences in duration of treatment and/or mechanism of action 
at the synapse could account for this discrepancy. Other factors 
such as diet and animal age can impact tryptophan metabolism 
and therefore the effect of fluoxetine. As our animals received the 
same standard chow diet and were of similar age, it is unlikely 
these parameters influenced the effect of fluoxetine.
Having found an upregulation of melatonin synthesis, we 
then investigated whether chronic fluoxetine alters expression 
of upstream cAMP signaling cascade elements in the pineal 
gland, such as the PDE and cyclase genes. We found that 
chronic treatment with fluoxetine increased the expression of 
two cAMP-specific PDE genes, PDE4B and PDE8B, while 
the expression of the cAMP-specific synthetic enzyme, AC1, 
was unchanged. Despite evidence that the PDE4 inhibitor 
rolipram displays antidepressant effects both in humans19,20 and 
rodents,21,22 PDE4 gene and protein expression is paradoxically 
increased after chronic antidepressant and electroconvulsive 
shock treatment in the cortex and hippocampus of rodents.23 
In contrast to our findings of increased expression of cAMP-
specific PDE isoforms, PDE4B and PDE8B, in the rat pineal 
following chronic treatment with fluoxetine, another study 
found that two weeks’ treatment with 3 mg/kg fluoxetine 
via osmotic minipump decreased pineal PDE4B mRNA as 
measured by ISH.24 The animals in the present study were 
euthanized four to six hours into the light cycle (from 10:00 
to 12:00); therefore, we have measured PDE gene expression 
during the light phase. PDE activity exhibits circadian rhythms 
in the rat pineal with highest levels during the dark phase and the 
lowest levels during the light phase.25 The circadian rhythmic-
ity of PDEs in the rat pineal also demonstrates sex differences, 
with two peaks of activity in male rats (from 2:00–4:00 am and 
again at 4:00 pm) versus only one peak (from 2:00–4:00 am) in 
females and castrated male rats.26 PDE4B mRNA demonstrates 
a specific circadian rhythm, with peak levels at night in the rat 
pineal four hours into the dark phase that progressively decline 
into the light phase. PDE4B2 levels are five-fold greater at night 
versus the day.27 As we did not measure PDE gene expres-
sion at different circadian timepoints, we cannot specifically 
comment on chronic antidepressant induced alterations in the 
Figure  Effect of chronic FLX treatment on a) AA-nAT gene expression levels in the pineal gland and b) plasma melatonin levels. AA-nAT gene expression results are 
expressed as mean ± SEM for FLX as percentage of SAL (n = 9–10 animals/group). Melatonin enzyme immunoassay results are expressed as mean ± SEM concentrations of 
plasma melatonin (in pg/mL) of rats treated chronically with SAL and FLX (n = 9–10/group).
Note: Asterisks indicate significant between-group differences (*p  0.05, ***p  0.001) using Student’s t-test.
Abbreviations: AA-NAT, arylalkylamine N-acetyltransferase; FLX, fluoxetine; SAL; saline-treated control; SEM, standard error of mean.
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circadian rhythms of PDEs in the pineal gland. However, our 
finding of increased PDE4B expression during the day sug-
gests that chronic fluoxetine treatment has altered the activity 
of the PDE system during its nadir, possibly causing a shift in 
the circadian rhythm.
To determine the consequence of altered PDE expression 
following chronic treatment with fluoxetine, we assayed the 
content of cAMP in the pineal gland using a competitive 
enzyme immunoassay. Since we found increased expression 
of cAMP-specific PDEs and unchanged expression of 
the cAMP-specific adenylate cyclase following chronic 
treatment, we predicted that cAMP levels would be decreased 
in the pineal gland chronically. Indeed, chronic fluoxetine 
was found to decrease pineal cAMP levels to half of the val-
ues seen in the saline group. These results are in agreement 
with our recent report of downregulated cAMP signaling in 
rats chronically treated with imipramine in which we found 
increased PDE, decreased AC, decreased cAMP levels, and 
unchanged cGMP levels.28 Similarly, in the pineal gland, con-
gruent findings of increased PDE expression, unchanged AC, 
and decreased cAMP levels suggest that repeated treatment 
with fluoxetine decreases cAMP signaling in the rat pineal. It 
is unclear why cAMP signaling was downregulated despite an 
upregulation of melatonin synthesis as indicated by increased 
pineal AA-NAT expression and plasma melatonin levels. It 
is possible that the downregulation of cAMP signaling might 
occur as a compensatory adaptation to bring the increased 
melatonin synthetic cascade back to baseline levels.
Several lines of evidence in rodents point to an influence 
of SSRIs such as fluoxetine on circadian rhythms. Fluoxetine 
inhibits light-induced phase advances in circadian wheel run-
ning behavior, alters clock gene expression in the SCN, and 
decreases REM sleep.29–32 Our finding of chronic fluoxetine 
induced increases in daytime plasma melatonin is consistent 
with the idea that antidepressants might normalize the phase 
advance in circadian rhythms that occurs with MDD by caus-
ing a shift in the pattern of melatonin secretion. As circadian 
secretion of the hormone melatonin peaks at night and declines 
during the day, it is possible that chronic antidepressant treat-
ment induces increases in daytime melatonin that could in 
turn affect sleep-wake cycles. The behavioral consequences 
of increased daytime melatonin are unclear, but possibly 
point to an improvement in the quality of sleep by decreasing 
early morning awakening, a common complaint in MDD. For 
example, melatonin supplements have been widely reported to 
have a sleep promoting effect when taken during the day, and 
therefore are used as a treatment for jet lag syndrome.33
In summary, chronic fluoxetine increased pineal 
AA-NAT expression and elevated daytime plasma melatonin 
despite decreased pineal cAMP content and increased pineal 
PDE gene expression. We conclude that repeated fluoxetine 
treatment increases melatonin synthesis in the rodent and 
alters pineal cAMP signaling.
Disclosure
Gillian W Reierson contributed to the conception and design 
of the study, the acquisition of data, the analysis and interpreta-
tion of data, and drafting of the article. Claudio A Mastronardi 
contributed to the conception and design of the study, the acqui-
sition of data, and revising the article for important intellectual 
content. Julio Licinio contributed to revising the article for 
important intellectual content and final approval of the version 
of the article to be published. Ma-Li Wong contributed to the 
a)
PDE4B
300
250
200
150
100
50
0
SAL FLX SAL FLX
PDE8B
AC1
m
R
N
A
 
(
%
 
o
f
 
s
a
l
i
n
e
-
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
 
Treatment group 
300
250
200
150
100
50
0
300
250
200
150
100
50
0
SAL FLX
SAL
c
A
M
P
 
L
e
v
e
l
s
(
p
m
o
l
/
m
L
)
Group (n = 9−10)
FLX
**
80
60
40
20
0
**
***
b)
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b) cAMP levels in the rat pineal gland. Gene expression results are expressed as 
mean ± SEM for FLX as percentage of saline-treated control (SAL) (n = 9–10 animals/
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